| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Total revenues, net | 120,700 | 110,565 | 2,732 | |
| Cost Of License Services And Royalty Revenue | - | 805 | - | |
| Product | 4,028 | - | - | |
| Cost Of Goods Sold | - | 2,848 | - | |
| License Services And Royalty | 2,535 | - | - | |
| Restructuring charges, total | - | - | 4,621 | |
| Total cost of revenues | 6,563 | 3,653 | 598 | |
| Research and development | 112,874 | 111,231 | 120,444 | |
| Selling, general and administrative | 137,621 | 129,154 | 68,819 | |
| Restructuring, impairment and related charges | 8,841 | 805 | - | |
| Total operating costs and expenses | 265,899 | 244,843 | 194,482 | |
| Loss from operations | -145,199 | -134,278 | -191,750 | |
| Interest income | 6,239 | 3,898 | 3,296 | |
| Interest expense | 11,739 | 37,637 | 23,061 | |
| Noncash interest expense on deferred royalty obligations | 36,410 | - | - | |
| Gain on deconsolidation of subsidiaries | 0 | 0 | 52,027 | |
| Loss on extinguishments of debt | 0 | 0 | - | |
| Net loss from equity method investments | -15,834 | -20,189 | -6,563 | |
| Other income, net | 16,461 | 6,548 | 1,797 | |
| Total other income (expense), net | -41,283 | -47,380 | 27,496 | |
| Loss before income taxes | -186,482 | -181,658 | - | |
| Provision for (benefit from) income taxes | -1,545 | 2,100 | - | |
| Net loss | -184,937 | -183,758 | -164,254 | |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | -2,194 | -1,855 | -2,214 | |
| Net loss attributable to common stockholders of bridgebio | -182,743 | -181,903 | -162,040 | |
| Net loss per share attributable to common stockholders of bridgebio, basic (in dollars per share) | -0.95 | -0.95 | -0.86 | |
| Net loss per share attributable to common stockholders of bridgebio, diluted (in dollars per share) | -0.95 | -0.95 | -0.86 | |
| Weighted-average shares used in computing net loss per share attributable to common stockholders of bridgebio, basic (in shares) | 191,854,152 | 190,517,215 | 188,510,372 | |
| Weighted-average shares used in computing net loss per share attributable to common stockholders of bridgebio, diluted (in shares) | 191,854,152 | 190,517,215 | 188,510,372 | |
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO)